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Abstract
Background: Time in therapeutic range (TTR) is a measurement of quality of warfarin therapy and lower TTR
values (<50%) are associated with greater risk of thromboembolic and bleeding events. Recently, we developed a
pharmacogenetic-based warfarin dosing algorithm specifically calibrated for a Brazilian patient sample. The aims
of this study are: to evaluate the impact of a genetic-based algorithm, compared to traditional anticoagulation, in the
time to achieve the therapeutic target and in TTR percentage; and to assess the cost-effectiveness of genotype-guided
warfarin dosing in a specific cohort of patients with low TTR (<50%) from a tertiary cardiovascular hospital.
Methods/design: This study is a randomized controlled trial in patients (n = 300) with atrial fibrillation with
TTR < 50%, based on the last three INR values. At the first consultation, patients will be randomized into two
groups: TA group (traditional anticoagulation) and PA group (pharmacogenetic anticoagulation). For the first group, the
physician will adjust the dose according to current INR value and, for the second group, a pharmacogenetic algorithm
will be used. At the second, third, fourth and fifth consultations (with an interval of 7 days each) INR will be measured
and, if necessary, the dose will be adjusted based on guidelines. Afterwards, patients who are INR stable will
begin measuring their INR in 30 day intervals; if the patient’s INR is not stable, the patient will return in 7 days for
a new measurement of the INR. Outcomes measures will include the time to achieve the therapeutic target and
the percentage of TTR at 4 and 12 weeks. In addition, as a secondary end-point, pharmacoeconomic analysis will
be carried out. Ethical approval was granted by the Ethics Committee for Medical Research on Human Beings of
the Clinical Hospital of the University of São Paulo Medical School.
Discussion: This randomized study will include patients with low TTR and it will evaluate whether a population-specific
genetic algorithm might be more effective than traditional anticoagulation for a selected group of poorly anticoagulated
patients.
Trial registration: ClinicalTrials.gov, NCT02592980. Registered on 29 October 2015.
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Background
Warfarin is a vitamin K antagonist and is the most
widely prescribed oral anticoagulant agent worldwide
[1]. It is used to prevent morbidity and mortality due to
thromboembolism and, for this reason, it is very import-
ant to achieve an optimal anticoagulant therapy [2]. Fur-
thermore, warfarin has a narrow therapeutic range and,
consequently, patients usually have difficultly achieving
and maintaining the therapeutic target [3–5].
Time in therapeutic range (TTR) is a measure of the
quality of warfarin therapy, i.e., the percentage of time a
patient’s INR (international normalized ratio) is within
the desired treatment target. Lower TTR values (<50%)
are associated with greater risk of thromboembolic and
bleeding events; while higher TTR values (>65%) are as-
sociated with therapeutic benefits [6, 7]. Some studies
identified factors that can affect TTR, such as the use
of age, gender, race, and concomitant medications for
predicting one’s ideal dosage [8–15]. In this scenario, some
studies have assessed the impact of pharmacogenetic algo-
rithms to guide the beginning of treatment. Pirmohamed
et. al followed-up, for 12 weeks, patients who were re-
cruited in the United Kingdom and Sweden. They used a
slightly modified version of the International Warfarin
Pharmacogenetics Consortium algorithm for predicting
maintenance doses. They identified that the mean per-
centage of TTR was higher in the genotype-guided
group (67.4%) compared with the control group (60.3%,
p < 0.001) [16]. Verhoef et al studied patients taking aceno-
coumarol or phenprocoumon recruited in the Netherlands
and Greece. They used an algorithm developed by
EU-PACT group for phenprocoumon and acenocoumarol
drugs [17]. They identified that genotype-guided dosing
did not improve the TTR during the first 12 weeks after
the initiation of therapy (61.6 and 60.2%, p = 0.52). How-
ever, they identified different TTR during the first 4 weeks
after the initiation of treatment comparing pharmacoge-
netic and control groups (52.8 and 47.5%, p = 0.02) [18].
Kimmel et al, studied patients from 18 clinical centers in
the United States. They used an algorithm developed
by the COAG group [19]. The authors concluded that
genotype-guided dosing of warfarin did not improve
anticoagulation control during the first 4 weeks of
therapy [20].
Recently, we developed a pharmacogenetic-based war-
farin dosing algorithm specifically tailored for Brazilian
individuals, a highly admixed population. It was shown
to be more accurate than internationally developed algo-
rithms for individuals from the Brazilian population [21].
Likewise, some other studies have shown that pharmaco-
genetic algorithms could be more accurate when devel-
oped and applied on specific populations [22–24].
Furthermore, studies showed the ability to improve TTR,
compared with traditional anticoagulation, using strategies
such as educational intervention, point-of-care testing, and
the use of family practice clinics [25–27]. In this context,
there is no data in the literature on the specific testing of a
pharmacogenetic algorithm in patients with low TTR
(<50%). In addition, cost-effectiveness evaluations for
this approach are scarce and a positive finding for a
pharmacogenetic approach could be very useful in a pro-
gram of individualized anticoagulation therapy [28–30].
Thus, the aims of this study are: to evaluate the impact
of a genetic-based, population-specific, algorithm, com-
pared to traditional anticoagulation, in the time to achieve
the therapeutic target and in the percentage of TTR at 4
and 12 weeks; and to assess the cost-effectiveness of
genotype-guided warfarin dosing in a specific cohort of
patients with low TTR (<50%) from a tertiary cardiovascu-
lar hospital.
Methods
Trial design
We will recruit 300 patients with low TTR (<50%) from
the Heart Institute- Clinical Hospital-University of São
Paulo Medical School (InCor- HCFMUSP).
The study protocol was approved by the Ethics Com-
mittee for Medical Research on Human Beings of the
Clinical Hospital of the University of São Paulo Medical
School (SDC 4033/14/013). Signed informed consent
will be obtained from all participants.
Figure 1 shows the study design. Physicians will select
the eligible patients according to the described criteria.
At the first consultation, the pharmacist will explain the
study and, if the patient accepts to participate, he or she
will then sign the term. Patients will be randomized into
two groups: TA group (traditional anticoagulation) and PA
group (pharmacogenetic anticoagulation). Randomization
will be considered protocol starting date. Pharmacists will
apply questionnaires and collect blood samples for DNA
extraction and measure creatinine, ASTand ALT.
Fig. 1 Flowchart of the study design
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For the TA group, the physician will adjust the dose
according to the current INR value based on current
guidelines [31, 32]. For the PA group, the dose will be
prescribed based on data from each patient applied in a
pharmacogenetic algorithm. In some cases, used algorithm
may provide a counter-intuitive dose, i.e., a dose that is
not adequate for adjusting the current patient’ INR (for
example, a higher dose for a patient that already has a high
INR). In these cases, the physician will adjust the dose fol-
lowing clinical criteria based on published guidelines and
these patients will be kept on PA group [3, 33]. Patients of
both groups will receive the medication and receive the
pharmaceutical care. On the day after randomization, the
pharmacist will inform, by phone, the new weekly dose
prescribed for patients of both groups.
At the second (7 days), third (14 days), fourth (21 days),
and fifth (28 days) consultations (with an interval of 7 days
each), warfarin dosage will be adjusted, if necessary, based
on current guidelines [31, 32].
After the fifth consultation, if the patient’s INR is
within therapeutic target, the next measurement will be
made after 30 days. If the patient’s INR is not in the
therapeutic target, the warfarin dose adjustment will be
made and the next INR measurement will be made after
7 days. The main outcomes will be the time to achieve
the therapeutic target and the percentage of TTR at 4
and 12 weeks. We will measure the INR of all patients at
the 12th week, independently of the value of INR before
of this endpoint.
Participants
Only patients with atrial fibrillation, above 18 years, and
with TTR <50% based on the last three values of INR
will be included in this study. Patients will be excluded if
they have reached a stable dose of warfarin, liver dys-
function, alcoholism, use of another anticoagulant, use
of chemotherapy, if they changed the dose of amioda-
rone 1 week before or if they do not meet the inclusion
criteria.
Interventions
For the TA group, the physician will adjust the dose
according to the current INR value based on current
guidelines [31, 32] and using an EP mobile tool for
dividing the weekly dose in the days with the availability of
tablets [34].
Patients with INR values <1.8 or >3.2 will undergo
dose adjustment. For patients with an INR value from
1.8 to <2.0 or from >3.0 to 3.2, warfarin dose will be
maintained and INR tests will continue to be made every
7 days. Then, if the patient continues to demonstrate
values from 1.8 to <2.0 or from >3.0 to 3.2, warfarin
dose will be changed. At each patient consultation, the
pharmacist will check the drug adherence counting pills
and adverse events using patient self-reporting informa-
tion. The average weekly warfarin dose will be changed
according to patient’s INR value: ≤1.5, increase by 20%;
>1.5–<2.0, increase by 5%; >3.0–3.5, decrease by 5%;
>3.5–<6.0, hold 1 dose, decrease by 15%; ≥6.0, hold war-
farin and consider vitamin K based on guidelines [31,
32].
For the PA group, the dose will be prescribed based on
data from each patient applied in a pharmacogenetic al-
gorithm for the first consultation, after will adjust the
dose based on guidelines and using the EP mobile [21].
Outcomes
We will use the time to achieve the therapeutic target as
primary outcomes measures and the TTR percentages as
second outcome measures. We will consider that achieve
the therapeutic target is three INR’s values within the
therapeutic target. We will calculate the TTR in 4 and
12 weeks of follow-up.
Sample size
With a sample size of 150 patients for each arm separ-
ately, the study will have a power of 80% to observe a
difference of 8% between TTR means of the TA and PA
groups, using sigma of 25% and alpha of 0.05.
Randomization
Patients will be randomized into two groups: TA group
(traditional anticoagulation) and PA group (pharmacoge-
netic anticoagulation). The randomization method will be
by original generator, which allowed for only one block
size. We will use the randomization.com to perform the
randomization automatically [35]. We will add two arms
with 150 subjects each. Afterward, we will include the list
of randomization on the REDCap. This web application
choose automatically the arm according to the list of
randomization in a way that the information can not be
change.
Blinding
In this study, patients will be blinded and will not know
their genetic results. The study team will not be blinded.
Laboratorial measures and questionnaires
Oral anticoagulant therapy will be assessed by the pro-
thrombin time (PT) in an automated coagulometric
method. Venous blood samples will be collected in tubes
containing sodium citrate 3.8%. INR calculation will be
obtained by the ratio PT of the patient/normal PT controls,
elevated to the international sensitivity index. Besides
current INR, past INR values will be checked in electronic
medical records. TTR will be calculated by the Rosendaal
method [36], which uses linear interpolation to assign an
INR value to each day between successive observed INR
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values. Peripheral venous blood will be collected into a BD
Vacutainer System® without anticoagulant for measure-
ments of serum creatinine, alanine aminotransferase (ALT),
and aspartate aminotransferase (AST) by colorimetric and
enzymatic assays.
Physicians and pharmacists will also complete a
questionnaire for each patient. These will include the
following variables: name, age, sex, body mass index,
smoking, weekly intake of alcoholic beverages, weekly
intake of dark green vegetables, comorbidities, results
of last INR values, adverse events, and other drug use.
In addition, the physician will evaluate the patients with
the CHADS2VASC2 and HAS-BLED scores [37–39]. The
CHADS2VASC2 score estimates stroke risk in patients
with atrial fibrillation. The variables are congestive heart
failure, hypertension, age ≥ 75, diabetes mellitus, a history
of stroke or transient ischemic attack symptoms and
vascular disease history [37, 38]. The HAS-BLED score
estimates the risk of major bleeding for atrial fibrillation pa-
tients on anticoagulation care. “HAS-BLED” is an acronym
for Hypertension (uncontrolled, systolic blood pressure
>160 mmHg), Abnormal liver (cirrhosis or bilirubin >2x
normal or AST/ALT/alkaline phosphatase >3x normal) and
renal function (dialysis, transplant, creatinine > 2.6 mg/dL),
Stroke history, Bleeding predisposition or Prior Major
Bleeding, Labile INRs (unstable/high INRs or TTR < 60%),
Elderly (age ≥ 65), Drugs (antiplatelet agents, nonsteroidal
anti-inflammatory) or alcohol usage (≥8 drinks/week) [39].
Each patient will have an individual record, which remains
with the group of pharmacists and physicians. This record
will provide information on current warfarin dose (mg/
week), daily dose, and INR values. Furthermore, each pa-
tient will have a card to register the warfarin daily dose.
The information gathered in the study will be man-
aged using REDCap (Research Electronic Data Capture)
tools hosted at the Clinical Hospital from the University
of São Paulo Medical School. REDCap is a secure, web-
based application designed to support data capture for
research studies [40].
Genotyping and predicted metabolic phenotypes
We will collect blood samples using the BD Vacutainer
System® containing K3EDTA (Becton Dickinson, USA).
We will use the QIAamp DNA Blood Kit (QIAGEN,
Hilden, Germany) to extract genomic DNA from peripheral
blood leukocytes. Genotyping of CYP2C9*2 (c.430C >T,
rs1799853), CYP2C9*3 (c.1075A > C, rs1057910), and
VKORC1 3673 (g.1639G > A, rs9923231) polymorphisms
will be detected by real time PCR assays using Taqman
probes (Applied Biosystems, CA, USA). We will use posi-
tive and negative reference samples to test along with the
unknown samples in each run. TaqMan probe assay IDs:
CYP2C9*2: C__25625805_10, CYP2C9*3: C___27104892_
10, VKORC1 3673: C__30403261_20.
Patients will be divided into three distinct predicted
phenotypes: extensive metabolizer (EM: wild-type geno-
types for the CYP2C9 polymorphisms - *1/*1), intermediate
metabolizer (IM: heterozygous genotypes for the loss-of-
function CYP2C9 polymorphisms - *1/*2 or *1/*3) and
poor metabolizer (PM: polymorphic homozygous or com-
pound heterozygous genotypes for the loss-of-function
CYP2C9 polymorphisms - *2/*2 or *3/*3 or *2/*3) [41, 42].
Pharmacogenetic algorithm
The pharmacogenetic algorithm used in this clinical study
was developed and validated by our group using two inde-
pendent patient cohorts. It includes the variables age, sex,
weight, height, self-declared race, use of amiodarone, use
of enzyme inducers, VKORC1 genotypes, and predicted
phenotypes according to CYP2C9 polymorphisms [21].
Pharmacoeconomic analysis
In these analyses we will evaluate the cost-effectiveness
of both groups (TA and PA) calculating the costs of the
genetic test, INR tests, and physician visits; and the ef-
fectiveness of the anticoagulation. We will also estimate
costs that will be used to calculate the QALYs (quality-
adjusted life year). These results that are used in QALYs
are major bleeding, major thromboembolic events, and
death. Major bleeding includes any episode of bleeding
that requires hospitalization and thromboembolic events
include embolic stroke, systemic embolism, ischemic at-
tacks, deep venous thrombosis and pulmonary embolism.
Statistical analysis
Statistical analyses will be carried out using SPSS soft-
ware (v. 16.0, IBM, New York, NY) and the level of sig-
nificance set at p ≤ 0.05. Pharmacoeconomic data will be
evaluated using the TreeAge software (TreeAge, Inc.,
Williamstown, MA). Chi-square tests will be performed
for comparative analysis of the categorical variables
(such as adverse events, and evaluation of percentage of
INR within therapeutic range) according to the polymor-
phisms or with the two approaches that will be made
(TA and PA). Students’ t-tests or Mann-Whitney tests
will be used for comparing TTR means and the time to
achieve the therapeutic range according to the two
groups. In addition, multivariate linear regression ana-
lysis will be used to identify variables associated with the
TTR mean and with the time necessary to achieve the
therapeutic range. A new randomization will not be per-
formed for substitution of patients with missing data.
Discussion
This randomized study will include patients with low
TTR from a cardiovascular tertiary hospital and it was
designed to evaluate whether a population-specific gen-
etic algorithm might be more effective than traditional
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anticoagulation for a selected group of poorly anticoagu-
lated patients.
Previous clinical trials tested genetic-based algorithms
in patients beginning warfarin therapy and found con-
trasting results [43]. However, no study to date has fo-
cused on this specific group of difficult to anticoagulate
patients.
Our study has some potential limitations. First, although
we will check the adverse effects during the study, we will
not be able to analyze them with adequate statistical
power. However, since these events may severely affect
cost-effectiveness analysis they are contemplated in the
study design. Second, we will use an algorithm modeled
from a Brazilian cohort of patients and it will be applied in
a specific group of patients of a tertiary referral hospital.
Thus, applicability of our findings will need of external
validity.
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